key: cord-1039717-o3k7pge5
authors: Kumar, S. Udhaya; Priya, N. Madhana; Nithya, S. R.; Kannan, Priyanka; Jain, Nikita; Kumar, D. Thirumal; Magesh, R.; Younes, Salma; Zayed, Hatem; Doss, C. George Priya
title: A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing
date: 2021-03-27
journal: 3 Biotech
DOI: 10.1007/s13205-021-02749-0
sha: f392c775aca8b575b5657b263dcfd61b1eeedfb2
doc_id: 1039717
cord_uid: o3k7pge5

Coronavirus disease (COVID-19) pandemic is instigated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of March 13, 2021, more than 118.9 million cases were infected with COVID-19 worldwide. SARS-CoV-2 is a positive-sense single-stranded RNA beta-CoV. Most COVID-19 infected individuals recover within 1–3 weeks. Nevertheless, approximately 5% of patients develop acute respiratory distress syndrome and other systemic complications, leading to death. Structural genetic analyses of SARS-CoV-2 have shown genomic resemblances but a low evolutionary correlation to SARS-CoV-1 responsible for the 2002–2004 outbreak. The S glycoprotein is critical for cell adhesion and the entrance of the virus into the host. The process of cell entry uses the cellular receptor named angiotensin-converting enzyme 2. Recent evidence proposed that the CD147 as a SARS-CoV-2′s potential receptor. The viral genome is mainly held by two non-structural proteins (NSPs), ORF1a and ORF1ab, along with structural proteins. Although NSPs are conserved among the βCoVs, mutations in NSP2 and NSP3 may play critical roles in transmitting the virus and cell tropism. To date, no specific/targeted anti-viral treatments exist. Notably, more than 50 COVID-19 candidate vaccines in clinical trials, and a few being administered. Preventive precautions are the primary strategy to limit the viral load transmission and spread, emphasizing the urgent need for developing significant drug targets and vaccines against COVID-19. This review provides a cumulative overview of the genomic structure, transmission, phylogeny of SARS-CoV-2 from Indian clusters, treatment options, updated discoveries, and future standpoints for COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13205-021-02749-0.

2020a; Li et al. 2020b; WHO 2020a) . The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the infection. The virus mainly affects the respiratory system leading to flu-like symptoms, including high temperature, coughing, and in more severe cases, breathing difficulty (Zou et al. 2020 ). Most patients recover in a period of 1-3 weeks; however, approximately 5% develop severe symptoms that may progress to acute respiratory distress syndrome (ARDS) and respiratory failure, which may cause death. Besides, in patients at high risk, COVID-19 may lead to systemic inflammation, putting patients at risk of sepsis, cardiac injury, and organ dysfunction . Older people (> 60 years) and people with other morbidities are at a higher risk of mortality .

Coronaviruses (CoVs) belong to the family of Coronaviridae that encompass four genera that include alpha-, beta-, gamma-, and delta-CoVs. Alpha-and beta-CoVs infect mammals and humans, while gamma-CoVs infect birds and delta-CoVs infect birds and mammals. The two most known types of human CoVs are the beta-CoV OC43 and the alpha-CoV 229E, both of which typically cause minor disease conditions, usually mild upper respiratory diseases that are self-limiting in individuals with a tolerable immune system (Sahin et al. 2020) . Other human coronaviruses include the Middle East respiratory syndrome coronavirus (MERS-CoV, 2013) , SARS-CoV-1 (2002) , and the novel SARS-CoV-2, all of them belong to beta-CoVs, are transmitted through zoonotic transmission (from animals to humans), then spread among humans via close contact causing severe diseases . Genomic characterization revealed that the sequences of SARS-CoV-2 exhibit high homology with that of the previously identified SARS-CoV-1 and weaker homology with MERS-CoV (Jaimes et al. 2020) .

Nevertheless, the clinical and epidemiological characteristics of SARS-CoV-2 are not precisely the same as that of SARS-CoV-1. SARS-CoV-2 is highly transmittable compared to SARS-CoV-1, with a 2.6 primary reproduction number (R0) of spread, implying that the number of SARS-COV-2 positive cases increases exponentially (Hellewell et al. 2020) . Moreover, SARS-CoV-2 has lower-level mortality compared to SARS-CoV-1. CoVs are enveloped viruses and have the most abundant RNA viral genome, with a length of 26 to 32 kb . The replication mechanism of CoVs is quite complicated to ease virus reproduction (Chen and Guo, 2016) . The virion's primary connection with the host cell takes place between the S protein and its receptor. The positions of receptor binding domains (RBD) vary depending on the structural changes (Fehr and Perlman 2015) . SARS-CoV-2 is spreading much faster than any other respiratory viruses. The incubation period of the virus ranges from 2-14 days, and a fraction of people likely transmit the infection without manifesting any symptoms of the disease (Martinez 2020) . Currently, there are no effective treatments for . Mutations in the genome of SARS-CoV-2 pose a significant challenge to researchers in drug and vaccine development (Xu et al. 2020a, b) . Currently, there are more than 118.9 million cases have been recorded worldwide, with India listed in the 2nd place of the most confirmed cases (Table 1) Udhaya Kumar et al. 2020; MOHFW 2020; WHO 2020a) . The top five states with the highest cases in India are provided in Table 1 . Besides, we provided a country-wise full case report, cumulative total per 1 million population, the total number of deaths, and classification of transmission till March 13, 2021 (Supplementary Table 1 ) (WHO 2020a) . This review aims to provide comprehensive insights into the genomic structure, transmission, treatment options, recent findings, and future standpoints towards COVID-19.

CoVs are known to possess the largest genomes among all known RNA viruses, with a length ranging from 25 to 31 kb. SARS-CoV-2 is a spherical enveloped consisting of singlestranded positive-sense RNA linked with a nucleoprotein inside a capsid comprising a matrix protein. The envelope has glycoprotein projections in a bear club-shape. The viral diameter is approximately 150-160 nm. The SARS-CoV-2 exhibits high sequence similarity with the bat-SL-CoVZC45 and bat-SL-CoVZXC2 (≈ 88% and 87%, respectively) while being less similar to SARS-CoV-1 and MERS-CoV (≈ 79% and 50%, respectively) .

A typical CoV genome contains protein-encoding domains (5′ non-basic) consisting of two-third of genome replicase genes and 3′ structural and non-essential accessory protein-coding domains (Masters 2006) . The cells that contain the virus produce seven to nine viral-specific messenger RNAs with ends of 3′ co-terminal (Masters 2006) . The mRNAs' entirety conveys similar master sequences that span 70-90 nucleotides at the end of 5′ (Lai et al. 1984 (Lai et al. , 1985 . At their 5′ ends, CoVs mRNAs have a leader sequence, which is common among them (Spaan et al. 1983 ), which comprises a transcription regulatory sequence (TRS-L) at the 3′ end that arranges part of the signal for transcription of the sub-genomic mRNA (Budzilowicz et al. 1985) . The transcriptional regulatory sequences (TRSs) of all CoVs incorporated the conserved core sequences (CS), consisting of 6-8 nucleotides, along with 5′ and 3′ flanking sequences (Sola et al. 2005) . Beta-CoVs comprise 5′-UCU AAA C-3′, a heptameric consensus sequence. Replication occurs shortly after the virus enters the infective cell, followed by virion transfection via the generation of entire-length genomic and sub-genomic intermediate negative strands (Yount et al. 2000) . There is a minimum of 6 open reading frames (ORFs) in the CoV structures' genomic and subgenomic regions. The SARS-CoV-2 genome contains 14 ORFs. The most significant part of the whole genome length is known to be the ORFa/b, the first of the ORFs, which encodes NSP1-16 (non-structural proteins), apart from Gamma-CoVs with the absence of NSP1. The polypeptides pp1a and pp1ab produced by − 1 frameshift among ORF1a and ORF1b are processed virally determined main protease (M pro ) or chymotrypsin-like protease (3CL pro ) and other minor proteases into 16 NSPs (Masters 2006) .

As revealed by the whole-genome sequence alignment of the NSP-coding regions, there is approximately 58% identity among the varying CoV strains. About 43% identity in the structural protein-coding regions implies that NSPs form the genome's conserved regions, while structural proteins are more diverse . The NSPs aid in replication of the genome, proteolytic cleavage, and development of sub-genomic mRNA (14-16 final products prepared for coronaviruses) are inscribed on gene one inside the 5′-proximate, which is two-third; whereas the structural proteins are inscribed on eight-nine genes inside the 3′-proximate, which is one-third of the coronavirus genome. The structural genes are positioned in the order of 5′ to 3′; they encode for viral proteins that include spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Overall, the SARS-CoV-2 genome is about 25-31 kb in size with a spherical structure containing 9,860 amino acids. The genome encodes for 13 ORF's, out of which the first one-third codes for NSPs, and the remaining make up the structural proteins. The CoV strains' identity varies in terms of the protein structure, where structural proteins show diverse structural characteristics.

Nucleotide detection assays (NDA) such as Next Generation Sequencing (NGS) and RT-PCR detection technologies were implemented to detect SARS-CoV-2 (Shey et al. 2020; NGS 2020, p. 19) . Compared to the sequencing/NGS technologies, RT-PCR remains a cheaper method to detect SARS-CoV-2 infection (Ai et al. 2020) . The results can be achieved by assessing the expectorated sputum, bronchoalveolar lavage, or endotracheal aspirate samples acquired from the respiratory tracts (Lambert-Niclot et al. 2020) . The tests are repeated for re-verification in positive results and negative cases with strong clinical suspicions (Hassan et al. 2020 ). The genetic material obtained from the mucus or salivary samples is amplified in the laboratory using RT-PCR. After retrieving a sufficient amount of the genetic material, the conserved regions of the CoV are determined. The probes have been used based on existing gene sequences published on Virological.org by the Shanghai Public Health Clinical Center & Public Health School, Fudan University, Shanghai, China, and subsequently confirmed by other labs. In the COVID-19 positive cases, the tests are repeated to confirm the viral particles' clearance before the patient's discharge. The testing for the infection will differ based on the country (Dong et al. 2020) . Several biosensors have been developed and identified for early SARS-CoV-2 detection (Behera et al. 2020) .

Commercial NDA such as SARS-CoV-2 RNA detection kits was discovered, and nearly 37 commercial detection kits were approved by FDA (Health 2020) . Non-commercial NDA, such as Loop-mediated isothermal amplification (LAMP) and RT-LAMP, is recognized as an optimistic method than PCR. It provides more sensitivity, specificity, product yield, and reaction efficiency (Ji et al. 2020) . Consequently, several other detection methods have been employed, such as NP antigen detection assay, Antibody detection assays targeting SP and NP viral proteins (Ejazi et al. 2020; Li et al. 2020c; Guo et al. 2020 ). CT findings have been used controversially as a surrogate diagnostic test. Chest CT has a vital role in diagnosing COVID-19. COVID-19 occurs with pneumonia symptoms in the initial stage, including dry cough, fever, chest congestion, and fatigue. Therefore, chest scan aids in the assessment of the disease extent condition and its follow-ups as it shows the patchy or diffuse asymmetric airspace opacities, which is an acute symptom of COVID-19. The initial scans showed a bilateral lung development pattern for around 40 patients out of 41 ICU patients (Hosseiny et al. 2020) . The multifocal peripheral ground glass imaging results are highly suspicious of COVID-19, which might show a rapid change in a short duration (Table 2) (Li et al. 2020d ).

SARS-CoV-2 encompasses four types of structural proteins, namely S, E, M, and N proteins. These four structural proteins share high sequence identity to that of SARS-CoV-1 and MERS-CoV. It is incorporated with hemagglutination (HE) and glycoprotein acetyl esterase, making SARS-CoV-2 distinct from other CoVs (Cascella et al. 2020) . The S proteins lie in the outermost sessions of the viral particle, ACE2, which is known to have an essential part in the action of transmembrane receptor recognition, which is used by the CoVs to make an entry into the host cell. Therefore, the host specificity and infectious nature of CoVs are determined chiefly by the S proteins (Letko et al. 2020 ). Among all proteins within the virus structure, M protein is perhaps the most effective and is present in considerably various extents; it also provides the virus's shape. Figure 1 depicts the SARS-CoV-2 mechanism in the host cell.

On the other hand, inside the virion, E protein exists in the least quantity and helps release the infected cells' viral particles (Nal et al. 2005; Ashour et al. 2020) . Simultaneously, the N protein attaches to the viral RNA, which is obligatory during viral assembly for wrapping the viral RNA into the viral components (Parameshwar et al. 2020 ). On the beta-CoV surface, the HE is located. It is similar to the influenza virus hemagglutinin. It provokes acetyl-esterase activity, characteristics of HE might enhance the pathogenesis and entrance of CoVs that involve proteins at its viral structure (Klausegger et al. 1999) . CoVs use the S proteins to initiate the binding with the host cell. The binding activation is carried out by furin, an enzyme in several humans' organs, including the lungs, small intestine, and liver (Callaway et al. 2020 ). The S protein and the furin enzyme activation are not the only factors; other human cells' elements make them more vulnerable to new SARS-CoV-2 infection. In human cells, it was shown that the S protein needs to bind to ACE2, which allows SARS-CoV-2 to cause infection in human cells (Wrapp et al. 2020) .

Experts suggested that furin inhibitors might be an effective therapeutic against COVID-19. Meanwhile, it is also recommended that blocking ACE2 might also be another feasible solution, stopping the CoV from cell entry (Coutard et al. 2020) . In CoV, the RNA genome is enclosed in the N protein, further embedded into an envelope (Fan et al. 2005; McBride et al. 2014) . The structural and NSPs are produced by sub-genomic + sense RNAs translation. After the formation of viral RNA components, the assembling of structural viral protein occurs in the virions. The budding and viral assembly occur in the endoplasmic reticulum-Golgi intermediate ).

The S protein is a 150 KDa class I fusion transmembrane protein found in its outer portion. The protein contains an alpha-helical coiled structure and is highly glycosylated as it includes N-glycosylation sites from 21 to 35. It gathers as trimers giving a crown shape (corona; crown in Latin). They usually contain two N-terminal spaces labeled S1 that are liable for binding the receptor and a C-terminal S2 space essential for fusion. The S1 spaces comprise two sub-domains: N-terminal space and C-terminal space. Both subdomains work as receptor restricting spaces and tie an assortment of protein and sugar (Robson 2020) . The SARS-CoV-2′s S protein attaches ten to multiple times more sturdily to the receptor ACE2 in people in contrast to that of the S protein of SARS-CoV-1 infection from 2002, which is liable for the simple spread of COVID-19 from individual to individual than different CoVs. The antibodies used against SARS-CoV-1 could not bind to the new SARS-CoV-2 S protein successfully; therefore, the vaccines or the antibodybased treatment should be unique for COVID-19. It is noteworthy that the proteases in host cells cleave the S1 domain instantly after the upstream of the S2 fusion peptide, which is anticipated to be the reason for protein activation through irreversible conformational changes (Walls et al. 2020) .

The E protein is a small integral membrane protein but perhaps the most enigmatic. It is primarily expressed in infected cells during the replication cycle, and only a minute fraction is integrated with the virus envelope. The E protein is essential in virus assembly and maturation (Schoeman and Fielding 2019). They have three domains: hydrophilic amino acid terminus consist of 7-12 amino acids, the transmembrane hydrophobic domain containing 25 amino acids, and a long C-terminal end with the majority of proteins. The transmembrane domain (TMD) comprises two nonpolar, impartial amino acids: Leu and Val give solid hydrophobicity to E-protein. The central region [TMD] is uncharged, which is flanked towards one side by the amino acid negatively charged and on the opposite side via carboxy end of variable charges, which together give the E peptide gross net charge of zero (Schoeman and Fielding 2019). The E protein of SARS-CoV contains a restricting theme called postsynaptic thickness protein 95 (PSD95), Drosophila plate enormous tumor silencer (Dlg1), Zonula occludes-1 protein Chan et al. 2020; Bianchi et al. 2020) . Genetic analysis of the E protein revealed that the protein sequences in SARS-CoV-2 exhibit high identity from Pangolin and Bat isolate. Besides, evidence revealed a distinctive feature of E variants of SARS-CoV-2 in the presence of Arg at position 69, which replaces Asp, Glu, and Gln in SARS-CoV-1 E homologous proteins. Besides, there is a deletion at position 70, which corresponds to Cys or Gly in the other homologous proteins and other existing variations at positions 37, 55 to 56, and at 72 (Bianchi et al. 2020) .

The M protein is considered the most extensive protein in CoV's structural membrane. The membrane bilayer has the domain of short NH2-terminal in the outer part of the virus. It constitutes the cytoplasmic domain, i.e., the long COOHterminus in the viral particle's internal part. It has a vital role in forming the intracellular viral structures without the S protein (Mousavizadeh and Ghasemi 2020). It does not appear to have an enzymatic function, and it is not an ideal target either. Recent evidence revealed structural differences distinctive for SARS-CoV-2M protein that might be linked to the cross-species transmission and viral properties. Several variants were identified in SARS-CoV-2 M protein, including Ser2, Gly3, Val57, Arg89, lle70, Ser85, and Met175 (Bianchi et al. 2020) . Although multiple sequence alignment revealed high structural similarity (~ 98%) between M protein variants in SARS-CoV-2 and counterparts from Pangolin and Bats, the N-terminal position exhibited a variation in position four of the SARS-CoV-2′s M protein, consisting of an insertion of a Ser residue. In contrast, in the homologous proteins, there was a deletion in the RaTG13 Bat and an Asp residue in Bat CoVZC45, CoVZXC21, and Pangolin MP789 isolates.

The N protein is primarily involved in binding to the virus's RNA genome, forming a shell around the nucleic acid.

During the viral assembly process, there is a connection between the N-protein and M-protein, assisting the RNA synthesis and folding, which is vital in the viral budding and disturbs the responses like cell cycle and translation in Fig. 1 The SARS-CoV-2 life cycle inside its host cell; starts when the S protein binding occurs with the ACE2 receptor. After the binding process, the S protein changes enable the fusion of the viral envelope via the cell membrane's endosomal pathway. Then the RNA is released from the SARS-CoV-2 inside the host cell. The translation of the RNA genome into the viral replicase polyproteins, which produces various viral particles. A sequence of subgenomic mRNAs are produced by discontinuous transcription and, at last, get translated into viral proteins. These viral proteins and RNA genome are organized in the endoplasmic reticulum and Golgi's virions, which are further transported through the vesicles, and finally, exocytosis occurs host cells. Recent evidence revealed that the SARS-CoV-2 N protein manifests high sequence similarity to SARS-CoV-1 (~ 90.5%) (Zeng et al. 2020) . Nevertheless, structural differences that are distinctive for SARS-CoV-2 were reported. Most of the variants identified in the N protein of SARS-CoV-2 were missense mutations (such as 203_204delinsKR, S194L, P13L, and S197L) and synonymous mutations (such as D128D and L139L), and fewer were deletion and insertion mutations (Koyama et al. 2020 ).

The SARS-CoV genome encodes many proteins, including the replicase gene, a vital element of the genome CoV, encoding for 16 NSPs that constitute two large polypeptides, PP1a PP1ab. Two types of cysteine proteases function on those PPs to activate the NSPs. Chymotrypsin-like cysteine protease cleaves the C-terminal end of these PPs, and the M pro processes the N-terminal end, which is called papainlike protease (PL pro ). PL pro excises the first three cleavage sites in the PPs, while CL pro cleaves the remaining 11 sites, resulting in 16 NSPs release (Prajapat et al. 2020a, b) . Researchers in Gladstone Institute, US, have identified SARS-CoV-2 protein-human protein interactions using affinity purification mass spectroscopy. They discovered 332 SARS-CoV-2 protein-human protein interactions, of which 66 druggable human proteins were identified to be targeted by 69 compounds, of which some are already FDA-approved and in clinical trials (Gordon et al. 2020 ). According to a recent study, the SARS-CoV-2 genome encodes 14 ORFs. In particular, 5′ Orf1a/Orf1ab encodes polyprotein, which is autoproteolytically processed to 16 NSPs [NSP1-NSP16]. These form the replicase/transcriptase complex (RTC) such as NSP1, the main protease (NSP5), 2′O-methyltransferases (NSP10/NSP16), the primase complex (NSP7-NSP8), papain-like protease (NSP3), a helicase/triphosphatase (NSP13), an exoribonuclease (NSP14), the primary RdRp (NSP12), and an endonuclease (NSP15) (Li 2016) . The NSP1 interacts with the DNA replication of the host pathway. The NSP5, NSP8, NSP13 interact with the epigenetic and gene expression regulatory pathway of the host. NSP6, NSP7, NSP10, NSP13, NSP15 interact with vesicle trafficking. NSP8 interacts with RNA processing and regulation of the host pathway. NSP9 interacts with the extracellular matrix and NSP8; NSP13 interacts with the host signaling pathway of the infection's replication mechanism that makes duplicates of its RNA genome . The original CoV' RdRp exists as mind-boggling with polymerase called NSP12 and some small proteins NSP7 and NSP8. It consists of a shape such as the right hand. The RdRp from SARS-CoV (2002) and SARS-CoV-2 having a similar dynamic site of RNA polymerization and indistinguishable amino corrosive arrangements. Scientists hypothesized that remdesivir drug inhibits the RdRp of SARS-CoV-2, for which the clinical trials have started to test the ability of this drug to the patients infected with SARS-CoV-2. However, it is not clear that how the mutant RdRp works with remdesivir, and a recent study found a potential compound with a higher affinity for both the native and mutant RdRp through virtual screening strategies (Thirumal et al. 2021) . The S, M, and E proteins form the envelope and protect the viral particle from external factors (Bianchi et al. 2020; Huang et al. 2020b; Thomas 2020) . In short, protein structures play a crucial role in drug targets. The S glycoprotein structure of SARS-CoV-2 utilizes the ACE2 receptor of the host for cell entry, followed by other viral proteins exhibiting their role for the viral mechanism inside the host cell.

A phylogenetic relationship of SARS-CoV-2′s genome was reported in many studies; this method was applied to investigate the phylogenetic relationships among the genomes of CoVs, which investigate the developmental pathways and their ancestral/hereditary genome in the host organism (Forster et al. 2020; Jaimes et al. 2020; Nie et al. 2020) . It is mainly applied to investigate human evolution; however, it was applied less in viral evolution (Forster et al. 2020 ). SARS-CoV-2 is an ancestry of beta-SARS-CoV that belongs to the Coronaviridae family. Unlike SARS-CoV, SARS-CoV-2 possess a distinct evolution and proteolytically-sensitive activation loop, which is believed to be responsible for its high contagiousness and pathogenicity (Jaimes et al. 2020) . Recent phylogenetic analyses demonstrated that SARS-CoV-2 was phylogenetically close to the RaTG13, accompanied by GD Pangolin SARSr-CoV, and by GX Pangolin SARSr-CoVs, and now by ZC45 and ZXC21, then by human SARS-CoV, and last by BM48-31 (Tang et al. 2020 ). As of March 13, 2021, more than 3,12,463 SAR-CoV-2 genome sequences are identified globally and available in the public domain. Based on the mutation marker, globally, six phylogenetic clades of SARS-CoV-2 were categorized (GH, S, GR, V, G, and L) (Jacob et al. 2020 ). Since the phylogenetic analysis of the SARS-CoV-2 genome was reported by Jacob et al. (2020) , our review focused on discussing the relationship between the phylogeny from Indian clusters to understand the genomic evolution (Jacob et al. 2020) . The sequences of SARS-CoV-2′s genomes reported in India, which belong to the genus Coronaviridae, were extracted from the GISAID initiative. Many national institutions collected the SARS-CoV-2 samples from different regions of India; their genomes were sequenced and deposited in the GISAID initiative (GISAID 2020). For our phylogenetic study, alignments of nucleotides were constructed with the help of Multiple Alignment using Fast Fourier Transform (MAFFT), and Block Mapping and Gathering with Entropy (BMGE) algorithm was applied to compute the appropriate locations for phylogenetic analysis in the query multiple sequence alignment and followed by FastME to compute the pairwise distances and tree (Desper and Gascuel 2002; Junier and Zdobnov 2010; Criscuolo and Gribaldo 2010; Katoh and Standley 2013; Lefort et al. 2015; Lemoine et al. 2019) . For further visualization of the output tree, we used the Interactive Tree Of Life (iTOL) (Letunic and Bork 2019) (Fig. 2) . The SARS-CoV-2 genomes from Indian isolates exhibited a common PANGOLIN lineage, which is highly transmissible (B.1/B.1.1/B.1.36) with mutation (D614G); whereas, the B.6 lineage reported as a second common and least transmissible owing to the absence of mutation in S protein (Jacob et al. 2020; Banu et al. 2020; Koyama et al. 2020) . Intriguingly, the Gujarat dominant linage B.1.36 contains one-three S protein mutations that would lead to higher infection rates. 

COVID-19 treatment requires clinical care, including aid in oxygen, fluid therapy, and support for other internal organs affected. Current potential therapeutics used against COVID-19 include antibodies, anti-virals, cell-based compounds, RNA-based compounds, anti-inflammatory agents, antimalarial agents, and protein-based antibiotics (Lu 2020) . Figure 3 Summarizes current pre-clinical and clinical treatments available to treat COVID-19 (Milken Institute 2020). Table 3 includes a comprehensive description of the clinical evidence for the therapies being studied and Supplementary Table 2 . Evidence showed that outpatients could be benefited from acquiring monoclonal antibodies against SARS-CoV-2 early. Bamlanivimab and casirivimab plus imdevimab monoclonal antibodies as anti-SARS-CoV-2 are provided via EUA for patients at high risk of disease progression. Remdesivir (Veklury), an anti-viral agent, is the only FDA-approved drug for the COVID-19 treatment. The course of therapy of remdesivir was found to be effectively tolerated but is not efficacious in critical COVID-19 cases (Ko et al. 2020; Wang et al. 2020b, c) . Other anti-viral agents, including hydroxychloroquine and chloroquine, umifenovir, lopinavir-ritonavir, favipiravir, and oseltamivir, are currently being analyzed in vivo and in vitro (Table 3, Supplementary Table 2 ) Biorender 2020) . Oseltamivir joined with direct antiinfection utilization, has been utilized to treat patients with SARS-CoV-2 (Huang et al. 2020a ). The adequacy and safety measures of lopinavir-ritonavir and interferon-α 2b in COVID-19 patients are still being investigated (Habibzadeh and Stoneman 2020) . In vitro evidence using the antiparasitic drug, ivermectin has effectively worked as a potential therapeutic against SARS-CoV-2 in 48 h. However, the safety and applicability in humans remain to be investigated (Caly et al. 2020) . In hospitalized patients who need supplemental oxygen, corticosteroids, including dexamethasone, have been shown to enhance longevity, with the overall benefit seen in patients requiring mechanical ventilation. Hence, dexamethasone usage in this condition is highly recommended (Horby et al. 2020; Jeronimo et al. 2020; Angus et al. 2020; Tomazini et al. 2020 ).

The crystal structures are always more reliable than computational models (Forrest et al. 2006) . The crystal structure of the M pro (PDB ID-6LU7) could be the potential drug target with this aspect. It was not limited to this availability, but protease was essential in replicating the virus (Patick and Potts 1998) . Replication occurs within the cytoplasm of the host cells that are infected. The coronaviruses' singlestranded RNA genome is released in the cytoplasm, where it is translated to form a replicase complex, which is then processed proteolytically into NSPs by viral proteases (van Boheemen et al. 2012; Kilianski et al. 2013) . This makes it an excellent choice to inhibit the replicating virus and henceforth the viral assembly and its release. Coronavirus proteases are known to be multifunctional. Studies have shown that coronavirus has the DUB and deISGylating to evade innate immune systems (Komander et al. 2009; Jeon et al. 2010) . Some of the mechanisms that the virus adapts to evade the immune system include (1) inhibition of the poly I: C by the protease leading to the activation of the TRIF and further the NF-κB signaling.

(2) Downregulation of the IFR3 phosphorylation, thereby preventing its dimerization, results in the signal cascade's termination.

(3) Protease is also known to repress the IFN signalling. (4) Protease can stabilize the Iκ Bα, in turn, inactivating the NF-κB, a transcription factor for the activation of the inflammatory cytokines. (5) Activation of NF-κB by TNFα is blocked by protease (Devaraj et al. 2007; Frieman et al. 2009; Clementz et al. 2010) . Protease inhibitors can bind to the protease, thereby activating the signaling pathway and release of proinflammatory cytokines, and hence are an excellent choice for the anti-viral agent.

The main protease of SARS-CoV-2, referred to as the 3C-like protease (3CL pro ), was identified as a target for postinfection drugs in March 2020. 3CL pro enzyme plays a crucial role in the replication and life cycle of the virus. The human immunodeficiency viruses (HIV) protease inhibitors lopinavir and ritonavir have evidence of activity against the coronaviruses, including SARS-CoV and MERS-CoV (Li and Clercq 2020; Kupferschmidt et al. 2020) . They have recently been proposed as a potential combination therapy against COVID-19 (Table 3 and Supplementary Table 2 ) (Kupferschmidt et al. 2020; Mullard 2020; Mishra et al. 2020 ). Nevertheless, a recent preliminary study in China of lopinavir/ ritonavir combination therapy found no effect in people hospitalized for COVID-19 . Efforts are currently directed towards identifying novel protease inhibitors that target the protease 3CL pro , such as GC376 (Supplementary  Table 2 ) (Ramajayam et al. 2011; Morse et al. 2020; Liu et al. 2020) . Other protease inhibitors include bromhexine hydrochloride (Table 3) , which reduced patients' mortality rate with COVID-19 (Ansarin et al. 2020) . Besides, it can reduce infection, which could be used to treat COVID-19 as a prophylactic treatment (Ansarin et al. 2020) . Oral camostat mesylate is another prophylactic option for treatment COVID-19 treatment (Table 3 and Supplementary Table 2) . Research findings have shown that it prevents the SARS-CoV-2 entry into the hosts, indicating its potential effectiveness in treatment (Hoffmann et al. 2020) . 

The global pharmaceutical industries face many challenges, including attenuation of the drugs and higher cost due to an increased number of years to bring a drug to the market and changes in the regulatory requirements (Pammolli et al. 2011; Waring et al. 2015) . Drug repurpositioning is also known as the reprofiling or repositioning of drugs. It is an approach to identify novel uses of the already established or approved drug to treat a new disease other than the first indication (Ashburn and Thor 2004) . In the early days, drug repurposing has been mostly expedient; once a drug is discovered, and the drug shows its effect on different sites other than the targeted site, it was taken for commercial manipulation (Pushpakom et al. 2019) . The advantages of the drug repurposing approaches are: (1) the risk of drug failure is shallow because the drug used for repositioning was already proven to be reasonably safe enough in pre-clinical, experimental models and also in the clinical trials;

(2) the time entailed for the development of a drug can also be reduced because of the pre-clinical testing and safety assessment, which has already been completed; and (3) only less fund is required for the development of a repurposing drug, depending on the stage and also the procedure of development (Breckenridge and Jacob 2019). The regulatory and phase III trial cost may remain the same, but the cost of phase I and II trial can be reduced or saved.

Researchers have started testing existing anti-viral drugs that are widely used to treat HIV in hopes that they might be able to fight the COVID-19 (Supplementary Table 2) . A randomized controlled trial of the combination of ritonavir and lopinavir, an anti-HIV drug, is also being tested (Huang et al. 2020a ). The trials with other identified anti-viral drugs against other viral diseases like Ebola may benefit from another anti-viral testing. The use of marketed drugs whose safety profile is known could be used as adjuncts to monotherapy. Combinatorial therapies with cyclosporin, ribavirin, lopinavir-ritonavir, interferon beta-1b, remdesivir, monoclonal antibodies can be tested to prevent or curb the infection (Beigel et al. 2019; Singh et al. 2020) . The replication of coronavirus and release in cytoplasm forms a replicase complex that is then processed proteolytically into NSPs by viral proteases (van Boheemen et al. 2012; Kilianski et al. 2013) . This makes it an excellent choice to inhibit replicating the virus and henceforth the viral assembly and its release. Since no specific drug or vaccine is identified and approved when we wrote the manuscript for COVID-19 treatment, the best medication to be followed is a repurposing of anti-viral drugs. There must be an imminent need to control the widespread SARS-CoV-2 transmission repurposing as an effective treatment to prevent the rapid spread. 

The on-going outbreak of COVID-19 induced by the novel SARS-CoV-2 has put the world on red caution as it continues spreading and causing more fatalities. Exploration endeavors are being completed to diminish the SARS-CoV-2 and its variants from spreading. Discovering medications is commonly known as a long process that takes time. Different computer-aided drug designs (CADD) are assessed as promising strategies among all these structure-based medication plans. Ligand-based medication configuration approaches are known as valuable and ground-breaking procedures in tranquilize revelation advancement. These strategies can be applied with atomic docking to virtual screening for potential lead identification and enhancement. Currently, computational instruments are utilized in pharmaceutical ventures and examination regions to improve the medication disclosure and advancement pipeline's viability and adequacy. On the other hand, understanding the host-virus relationships and transcriptomic profiles of COVID-19 patients will prioritize gene targets that will lead to developing therapeutic drugs (Alsamman and Zayed 2020).

The COVID-19 outbreak has put health systems on a red alert as it quickly spreads globally. Old individuals and patients with chronic diseases are at high risk of developing severe symptoms and potential death from COVID-19. Researchers worldwide are struggling and trying hard to find effective treatments for COVID-19. In addition, drug repurposing can be achieved using existing FDA-approved anti-viral drugs for COVID-19. Since the described drugs are FDA-approved, their efficacy in treating the infection is expected to be less toxic to patients. This could lower the disease's severity in elderly patients and protect lives. The M pro , S glycoproteins, PL pro , RdRp, and 3CL pro of COVID-19 can be targeted using novel inhibitors or existing drug inhibitors to disable its infection ability altogether. Furthermore, the nanoemulsions, nanospheres, nanoparticles, nano-gels, liposomes, and nanosuspensions can be used for anti-viral drug delivery. This also defines and proposes an approach to address existing key challenges, thus directing scientists worldwide to perhaps refining the delivery of nano-based drugs as a strategy to combat virus outbreaks successfully. Further understanding of the molecular pathology of COVID-19 is expected to help in the discovery and development of drugs against COVID-19. 

Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned

The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial

Drug repositioning: identifying and developing new uses for existing drugs

Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks

A distinct phylogenetic cluster of Indian SARS-CoV-2 isolates

Biosensors in diagnosing COVID-19 and recent development

Advances in respiratory virus therapeutics-a meeting report from the 6th isirv Antiviral Group conference

Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? In: BioMed Research International

COVID-19 vaccine tracker-BioRender

Overcoming the legal and regulatory barriers to drug repurposing

Three intergenic regions of coronavirus mouse hepatitis virus strain A59 genome RNA contain a common nucleotide sequence that is homologous to the 3' end of the viral mRNA leader sequence

The coronavirus pandemic in five powerful charts

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

2020) Features, evaluation and treatment coronavirus (COVID-19)

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Molecular mechanisms of coronavirus RNA capping and methylation

Emerging coronaviruses: genome structure, replication, and pathogenesis

Deubiquitinating and interferon antagonism activities of coronavirus papainlike proteases

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade

BMGE (Block Mapping and Gathering with Entropy): a new software for selection of phylogenetic informative regions from multiple sequence alignments

Fast and accurate phylogeny reconstruction algorithms based on the minimum-evolution principle

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Eleven faces of coronavirus disease

Antibody detection assays for COVID-19 diagnosis: an early overview

The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its n-terminal domain and multimerization properties

Coronaviruses: an overview of their replication and pathogenesis

On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins

Phylogenetic network analysis of SARS-CoV-2 genomes

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling

Genomic epidemiology of hCoV-19

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)

The novel coronavirus: a bird's eye view

Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment

Coronavirus Disease 2019 (COVID-19) Emergency use authorizations for medical devices

Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in India and vaccine impact

Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop

and immune diseases

Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized double-blind phase IIb placebo-controlled trial

Detection of COVID-19: a review of the current literature and future perspectives

The Newick utilities: high-throughput phylogenetic tree processing in the Unix shell

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

Assessing activity and inhibition of middle east respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferasebased biosensors

Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Breaking the chains: structure and function of the deubiquitinases

Variant analysis of SARS-CoV-2 genomes

The rise and impact of COVID-19 in India

WHO launches global megatrial of the four most promising coronavirus treatments

Characterization of leader RNA sequences on the virion and mRNAs of mouse hepatitis virus, a cytoplasmic RNA virus

Recombination between nonsegmented RNA genomes of murine coronaviruses

Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs

FastME 2.0: a comprehensive, accurate, and fast distance-based phylogeny inference program

NGPhylogeny.fr: new generation phylogenetic services for non-specialists

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Interactive Tree Of Life (iTOL) v4: recent updates and new developments

Structure, function, and evolution of coronavirus spike proteins

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Bat origin of a new human coronavirus: there and back again

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

The epidemic of 2019-novelcoronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

The molecular biology of coronaviruses

The coronavirus nucleocapsid is a multifunctional protein

COVID-19 Treatment and vaccine tracker

An overview of COVID-19 with an emphasis on computational approach for its preventive intervention

MOHFW (2020) India-COVID-19 statewise status

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Genotype and phenotype of COVID-19: their roles in pathogenesis

Flooded by the torrent: the COVID-19 drug pipeline

Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins

NGS (2020) First NGS-based COVID-19 diagnostic

Phylogenetic and phylodynamic analyses of SARS-CoV-2

The productivity crisis in pharmaceutical R&D

A review novel coronavirus

Protease inhibitors as antiviral agents

Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence

Update on the target structures of SARS-CoV-2: a systematic review

Drug targets for corona virus: a systematic review

Drug repurposing: progress, challenges and recommendations

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and antipicornavirus drug discovery

COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance

novel coronavirus (COVID-19) outbreak: a review of the current literature

Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?

Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19

Role of nucleotides immediately flanking the transcription-regulating sequence core in coronavirus subgenomic mRNA synthesis

Coronavirus mRNA synthesis involves fusion of non-contiguous sequences

On the origin and continuing evolution of SARS-CoV-2

Structure-based virtual screening to identify novel potential compound as an alternative to remdesivir to overcome the RdRp protein mutations in SARS-CoV-2

The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

Kerala, India's front runner in novel coronavirus disease (COVID-19)

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

An analysis of the attrition of drug candidates from four major pharmaceutical companies

WHO (2020b) The COVID-19 candidate vaccine landscape

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

An update on current therapeutic drugs treating COVID-19

Effective treatment of severe COVID-19 patients with tocilizumab

Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV

Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Acknowledgements Mr. Udhaya Kumar S., one of the authors, gratefully acknowledges the Indian Council of Medical Research (ICMR), India, for providing him a Senior Research Fellowship [ISRM/11(93)/2019]. The authors would like to take this opportunity to thank the management of VIT for providing the necessary facilities and encouragement to carry out this work.Author contributions SUK, CGPD, and HZ were involved in the design of the review. SUK, DTK, NMP, NJ, SRN, PK, MR, SY, HZ, and CGPD were involved in drafting the manuscript. CGPD, HZ, and MR supervised the entire study design, the acquisition, and the drafting of the manuscript. The manuscript was reviewed and approved by all the authors.Funding Not applicable for the present study.

The authors have declared that no conflicts of interest exist.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s13205-021-02749-0.